Thermo Fisher Scientific Appoints New Members to Scientific Advisory Board

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has appointed three new members to its Scientific Advisory Board: Dr. Andrea Califano, Dr. Arnold J. Levine and Dr. Aviv Regev.

"As pioneers in their fields of study, Andrea, Arnold and Aviv are strong additions to our Scientific Advisory Board"
Dr. Califano is the founding chairman of the department of systems biology at Columbia University, and he currently serves on the board of scientific advisors of the National Cancer Institute. He is also professor of biomedical informatics at Columbia University.

Dr. Levine is professor emeritus of systems biology at the Institute for Advanced Study in Princeton, N.J. and professor of pediatrics and of biochemistry with the Robert Wood Johnson Medical School at Rutgers, the State University of New Jersey.

Dr. Regev is a core member of the Broad Institute and an associate professor of biology at the Massachusetts Institute of Technology. She is also an investigator at the Howard Hughes Medical Institute.

"As pioneers in their fields of study, Andrea, Arnold and Aviv are strong additions to our Scientific Advisory Board," said Marc N. Casper, president and chief executive officer of Thermo Fisher. "They bring a depth of understanding from the academic and research communities that will help inform our strategies for advancing our customers' work in computational and systems biology, genomics and cancer research."

The Scientific Advisory Board, established in 2010 to formalize the two-way exchange of technological information between the company and representatives from some of the world's premier centers of health, science, and education, also includes the following members:

Steven P. Gygi, PhD, Professor, Harvard Medical School, Department of Cell Biology
William C. Hahn, MD, PhD, Associate Professor, Harvard Medical School, Dana-Farber Cancer Institute, Department of Medical Oncology
Klaus Lindpaintner, MD, MPH, Chief Scientific Officer, Analytical Instruments, Thermo Fisher Scientific
Edison T. Liu, MD, President and CEO, The Jackson Laboratory
Tyler Jacks, PhD, David H. Koch Professor of Biology and Director of the David H. Koch Institute for Integrative Cancer Research at MIT, and Investigator at the Howard Hughes Medical Institute (also a member of Thermo Fisher's Board of Directors)
Iain Mylchreest, VP of R&D, Chromatography and Mass Spectrometry, Thermo Fisher Scientific
David M. Sabatini, MD, PhD, Professor, Whitehead Institute for Biomedical Research and MIT
Alan Sachs, Chief Scientific Officer, Life Sciences Solutions, Thermo Fisher Scientific
About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of $17 billion and 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our four premier brands – Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit


Thermo Fisher Scientific Inc.
Media Contact Information:
Ron O'Brien, 781-622-1242
[email protected]
Investor Contact Information:
Ken Apicerno, 781-622-1294
E-mail: [email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

City of Hope and Canadian biotech Biovaxys Technology reported positive animal data for their COVID vaccines that could offer alternatives to mRNA.

4D is adding a trio of executives to spearhead its work in heart, eye and lung diseases as it pushes programs into and through the clinic.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.